Refine your search

Search Results within category "Skin Conditions"

Search all categories
Study matches: 16

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.


PaTH Study for the Development of Outcome Measures for Hidradenitis Suppurativa (HS)

The purpose of the PaTH Study for the Development of Outcome Measures for HS is to work with patients and clinicians to develop and validate novel outcome measures for patients with HS. The primary objective is to develop validated patient- and clinican-reported outcome measures for hidradenitis suppurativa. Creating the PaTH Study for the Development of Outcome Measures for HS will involve: 1. Recruiting both patients with a history of HS and clinicians who have experience treating HS into the study 2. Conducting focus groups with patients and clinicians either using focus groups. These focus groups will consist of either patients of the same sex OR clinicians. 3. Developing, piloting, then validating a patient-reported outcomes measure (PROM; aim 1) as well as a clinician- reported outcome measure (CROM; aim 2). 4. Issue surveys for demographics, HS-PROM, and Skindex-16 for patients during validation and evaluation of responsiveness (aim 3). The target study population is: 1) Adults (patients aged 18 years or older) who receive health care at one of the four PaTH Network institutions involved in this study (Penn State, Pittsburgh, Giesinger, and Johns Hopkins) and have a documented diagnosis of HS in the EHR. 2) Clinicians who have familiarity treating patients with HS from 4 PaTH sites.
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
patients with Hidradenitis suppurativa
must be 18 years or older
fluent in English
Exclusion Criteria:
cannot read or speak English
under 18 years of age
do not have Hidradenitis suppurativa
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Mechanisms of neurovascular dysfunction in psoriasis patients

The purpose of this study is to determine what leads to blood vessel and nervous system dysfunction and the increased risk of cardiovascular disease in adults with psoriasis. Psoriasis is an independent risk factor for cardiovascular disease, because cardiovascular disease and psoriasis share common underlying inflammatory causes. This study may lead to treatment and/or prevention strategies to reduce cardiovascular disease risk in psoriasis patients. We explore 1) changes in nitric oxide that could make the body less able to relax blood vessels and 2) changes in sympathetic nervous system function that may contribute to increased cardiovascular disease risk in psoriasis patients. We will investigate the effect of oral salsalate administration on neural and blood vessel function in adults with psoriasis. The study includes experiments that examine blood vessel function in small vessels in the skin and nerve activity in the leg.
Billie Alba at bka125@psu.edu or 814-863-8557
All
18 year(s) or older
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Men and women (18-65 years)
Apparently healthy
Exclusion Criteria:
Pregnant or Breastfeeding
Allergies to NSAIDs or aspirin
Bleeding disorders or history of gastrointestinal bleeding
Renal disease
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

Atopic Dermatitis (AD): Topical Cream, Pediatrics 2-17 years old with active AD. This is a 4 week study with a follow up 1 month after the end of treatment.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Mild Atopic Dermatitis (AD) severity
Parent or legal guardian consent
Exclusion Criteria:
History of Hep B, Hep C, or HIV
AD only on hands or feet
Show full eligibility criteria
NCT03257644
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Identifying needs for dietary research for individuals with hidradenitis suppurativa

We will be exploring how patients perceive diet affects their HS to identify needs for continuing research in how diet affects HS.
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Must have HS
Access to computer/internet
English-Speaking
Exclusion Criteria:
Under the age of 18
Does not have HS
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (STUDY FX2017-22)

Acne study: Topical foam applied once daily for 12 weeks. Ages 9 years and older, up to 7 visits over 18 weeks. Compensation provided for time and travel.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
moderate to severe acne
Exclusion Criteria:
sunburn on the face
drug addiction or alcohol abuse
current or significant past history of depression
hepatitis, liver damage, renal impairment
Show full eligibility criteria
NCT03271021
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Suppurative

HS Study: 2:1:1 ratio, 9 treatment days. Ages 18-70 years, up to 12 visits over 34 weeks. Compensation provided for time and travel.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 1 year
HS lesions in at least 2 affected areas
Exclusion Criteria:
Acute or chronic Hepatitis B, Hepatitis C or HIV infection
Immunosuppressive condition, including immunosuppressive therapy following organ transplant
Had a splenectomy
History of lymphoma or myelitis
Show full eligibility criteria
NCT03248531
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Subject and Investigator Blinded, Placebo-Controlled, Multi-Center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients with Moderate to Severe Inflammatory Acne

Phase 2, 38 week, Moderate to Severe Acne trial randomized to one of 3 treatment sequences of CJM112 dosing administered by Sub-Q injection.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Moderate acne severity
Exclusion Criteria:
Severe nodulocystic acne
pregnant or nursing (lactating) women
History of immunodeficiency diseases
Active Crohn's disease
Show full eligibility criteria
NCT02998671
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of RVT-501 Topical Ointment in Pediatric Patients with Mild to Moderate Atopic Dermatitis

Atopic Dermatitis study: Topical Ointment applied 2 times a day. Ages 2-17 years, 6 visits over 4 weeks with an optional open-label extension phase. Compensation provided for time and travel.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
History of Atopic Dermatitis
Exclusion Criteria:
Certain treatments for Atopic Dermatitis are not allowed coordinator will discuss specific treatments.
Current of history of cancer within 5 years
Show full eligibility criteria
NCT03394677
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa

Male and female subjects with HS who are being considered to have surgery will be randomized to receive treatment of Humira or Placebo. There are three phases of the study during the 24 weeks.
Logan Claar at lclaar@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Exclusion Criteria:
Prior treatment of Humira or other biologics for the treatment of HS
Show full eligibility criteria
NCT02808975
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2a, Double Blind, Placebo Controlled Study of RSLV-132 In Subjects With Systemic Lupus Erythematosus

RSLV-132 is an investigational drug being developed for the treatment of autoimmune diseases such as Systemic Lupus Erythematosus (SLE, also referenced as lupus) which is affecting your skin.
Jamie Carter at jcarter3@pennstatehealth.psu.edu or 717-531-4921
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must have diagnosis of SLE according to the ACR criteria
Must have skin disease manifestations
Have elevated autoantibodies on lab resutls
Must be between the ages of 18-70
minimum weight of 45kg
Exclusion Criteria:
Recent use of immunosuppressive drugs
Current active infections
Pregnant or breast feeding
Show full eligibility criteria
NCT02660944
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluation of computerized technologies for counting acne lesions

In this study we will evaluate new computer technologies for assessing acne lesions in facial photographs of patients. Patients will come for a 1 hour session where there acne will be counted by 2 expert clinicians. Photographs of the face will be taken and the computer software will count the acne on the photographs. The counts obtained by the computer will be compared to the counts obtained by the clinicians and the software will be adjusted to be closer to the data obtained by the clinicians.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Ages 14 years and older.
Acne on the face
Exclusion Criteria:
Adolescents age 13 and younger
no acne
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Identifying the role that support groups play in the lives of patients with hidradenitis suppurativa.

The objective of this study is to explore how the participation in support groups affects the lives of patients with hidradenitis suppurativa (HS).
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Have Hidradenitis Suppurativa (also called acne inversa)
Be 18 years of age or older
Be able to read and write in English
Exclusion Criteria:
Does not have hidradenitis suppurativa
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team

An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Open label ACZONE 7.5% topical medication one time a day dosing for 9-11 yr olds with Acne vulgaris for 12 weeks. 7 visits to the Research Office.
Tori Ruyak at truyak@pennstatehealth.psu.edu or 717-531-1513
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
9-11 years of age
Male and Female
Mild, Moderate or Severe Acne
Exclusion Criteria:
Subjects who have less than 20 but no more than 100 inflammatory
or non-inflammatory acne lesions.
Show full eligibility criteria
NCT02959970
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severly Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE): Oral medication, Females 18-75 years old with Moderate-to-Severe Active CLE. This is a 24 week study with the option of a 24 week extension period.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Stable dose of antimalarials and topical/oral corticosteroids
No evidence of active or latent TB
Exclusion Criteria:
Have highly active inflammatory/autoimmune/rheumatic disease
Positive test result for HIV
Positive for Hepatitis C / Hepatitis B
Major surgery within 30 days prior to study start
Show full eligibility criteria
NCT03134222
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis

Pediatric Psoriasis clinical trial for ages 2-11 years, open-label foam applied twice daily.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Some scalp involvement needed
Exclusion Criteria:
certain treatments are not allowed; coordinator will discuss specific treatments
Show full eligibility criteria
NCT01582932
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Influences of Skin Microbiome on Acne Pathogenesis Related to Pubertal Development

We are investigating whether the changes in skin microbiome as related to pubertal age contribute to the development of acne
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Ages 7-17 years
1 time visit
compensation provided for time and travel
Exclusion Criteria:
Certain treatments for Acne are not allowed; coordinator will discuss specific treatments
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA